EP2306 and EP2302, Two Novel Squalene Synthase Inhibitors, Stimulate Endothelial Nitric Oxide Synthase Expression in Cultured Endothelial Cells

REFERENCES

• Bult H., Herman A. G., Matthys K. E. Antiatherosclerotic activity of drugs in relation to nitric oxide function. European Journal of Pharmacology 1999; 375: 157–176
   PubMed Web of Science ®Google Scholar
• Burnett J. R. Drug evaluation: TAK-475—An oral inhibitor of squalene synthase for hyperlipidemia. Current Opinion in Investigational Drugs 2006; 7: 850–856
   PubMed Web of Science ®Google Scholar
• Busse R., Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Letters 1990; 265: 133–136
   PubMed Web of Science ®Google Scholar
• Charlton-Menys V., Durrington P N. Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential. Drugs 2007; 67: 11–16
   PubMed Web of Science ®Google Scholar
• Chrysselis M. C., Rekka E. A., Kourounakis P N. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. Journal of Medicinal Chemistry 2000; 43: 609–612
   PubMed Web of Science ®Google Scholar
• Chrysselis M. C., Rekka E. A., Siskou I. C., Kourounakis P. N. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. Journal of Medicinal Chemistry 2002; 45: 5406–5409
   PubMed Web of Science ®Google Scholar
• Feron O., Belhassen L., Kobzik L., Smith T. W., Kelly R. A., Michel T. Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. Journal of Biological Chemistry 1996; 271: 22810–22814
   PubMed Web of Science ®Google Scholar
• Forstermann U., Pollock J. S., Schmidt H. H., Heller M., Murad F. Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1991; 88: 1788–1792
   PubMed Web of Science ®Google Scholar
• Fulton D., Gratton J.-P., Sessa W. C. Post-translational control of endothelial nitric oxide synthase: Why isn't calcium/calmodulin enough?. Journal of Pharmacology and Experimental Therapeutics 2001; 299: 818–824
   PubMed Web of Science ®Google Scholar
• García-Cardeña G., Fan R., Stern D. F., Liu J., Sessa W. C. Endothelial nitric oxide is regulated by tyrosine phosphorylation and interacts with caveolin-1. Journal of Biological Chemistry 1996; 271: 27237–27240
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation 1998; 101: 2711–2719
   PubMed Web of Science ®Google Scholar
• Hiyoshi H., Yanagimachi M., Ito M., Ohtsuka I., Yoshida I., Saeki T., Tanaka H. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: Comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. Journal of Lipid Research 2000; 41: 1136–1144
   PubMed Web of Science ®Google Scholar
• Ignarro L. J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annual Reviews of Pharmacology and Toxicology 1990; 30: 535–560
   PubMed Web of Science ®Google Scholar
• Ju H., Venema V. J., Marrero M. B., Venema R. C. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. Journal of Biological Chemistry 1998; 273: 24025–24029
   PubMed Web of Science ®Google Scholar
• Ju H., Zou R., Venema V. J., Venema R. C. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. Journal of Biological Chemistry 1997; 272: 18522–18525
   PubMed Web of Science ®Google Scholar
• Kawashima S., Yokoyama M. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arteriosclerosis Thrombosis and Vascular Biology 2004; 24: 998–1005
   PubMed Web of Science ®Google Scholar
• Laufs U. Beyond lipid-lowering: Effects of statins on endothelial nitric oxide. European Journal of Clinical Pharmacology 2003; 58: 719–731
   PubMed Web of Science ®Google Scholar
• Laufs U., Fata V. L., Plutzky J., Liao J. K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129–1135
   PubMed Web of Science ®Google Scholar
• Li D., Mehta J. L. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors protect against oxidized low-density lipoprotein-induced endothelial dysfunction. Endothelium 2003; 10: 17–21
   PubMed Web of Science ®Google Scholar
• Liao J. K., Shin W. S., Lee W. Y., et al. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. Journal of Biological Chemistry 1995; 270: 319–324
   PubMed Web of Science ®Google Scholar
• Michel T., Feron O. Nitric oxide synthases: Which, where, how, and why?. Journal of Clinical Investigation 1997; 100: 2146–2152
   PubMed Web of Science ®Google Scholar
• Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacological Reviews 1991; 43: 109–142
   PubMed Web of Science ®Google Scholar
• Napoli C., de Negris F., Williams-Ignarro S., Pignalosa O., Sica V., Ignarro L. J. Nitric oxide and atherosclerosis: An update. Nitric Oxide 2006; 15: 265–279
   PubMed Web of Science ®Google Scholar
• Nishimoto T., Amano Y., Tozawa R., Ishikawa E., Imura Y., Yukimasa H., Sugiyama Y. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. British Journal of Pharmacology 2003; 139: 911–918
   PubMed Web of Science ®Google Scholar
• Tavridou A., Kaklamanis L., Megaritis G., Kourounakis A. P., Papalois A., Roukounas D., Rekka E. A., Kourounakis P. N., Charalambous A., Manolopoulos V. G. Pharmacological characterization of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. European Journal of Pharmacology 2006; 535: 34–42
   PubMed Web of Science ®Google Scholar
• Tavridou A., Manolopoulos V. G. Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. European Journal of Pharmacology 2004; 505: 213–221
   PubMed Web of Science ®Google Scholar
• Ugawa T., Kakuta H., Moritani H., Inagaki O. Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. British Journal of Pharmacology 2002; 137: 561–569
   PubMed Web of Science ®Google Scholar
• Witztum J. L., Steiberg D. Role of oxidized low-density lipoprotein in atherogenesis. Journal of Clinical Investigation 1991; 88: 1785–1792
   PubMed Web of Science ®Google Scholar